Back to Market返回行情

ELAN Elanco Animal Health Incorporated

USHealthcare
$24.69+0.20%ClosedMarket Cap: $12.33B

As of 2026-07-08 16:00

Why ELAN matters now

Elanco Animal Health Incorporated (ELAN) is a US stock in Healthcare. The latest InvestLog snapshot shows $24.69 with +0.20% on the session and $12.33B in market capitalization; recent performance reads 1-month +22.32% and YTD +7.03%.

The latest financial table shown here is Q1 2026, with revenue of $1.37B, net income of $57.0M, and EPS of $0.11. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 2.6%.

The latest indexable market news headline is "Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement" from PRNewsWire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $30.00; recent insider activity includes Modi Rajeev A. filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

1.85

P/S

2.47

EV/EBITDA

20.50

DCF Value

$5.37

FCF Yield

2.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

49.4%

Operating Margin

9.0%

Net Margin

-4.9%

ROE

-3.6%

ROA

-1.8%

ROIC

3.8%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$1.37B$57.0M$0.11
Q4 2025$1.14B$-276.0M$-0.55
FY 2025$4.71B$-232.0M$-0.47
Q3 2025$1.14B$-34.0M$-0.07

Analyst Ratings

Consensus

Buy

Target (Consensus)

$28.40

Target (Median)

$30.00

Target Range

$23.00 - $30.00

Strong Buy: 5Buy: 11Hold: 2Sell: 0Strong Sell: 0
TD CowenBuy
2026-06-18
CitigroupBuy
2026-05-07
JP MorganOverweight
2026-05-07
Morgan StanleyEqual Weight
2026-02-25
KeybancOverweight
2026-02-25

Trading Activity

Insider Trades

Modi Rajeev A.officer: SEE REMARKS
Sell2026-06-16
Simmons Jeffrey Ndirector, officer: PRESIDENT, CEO AND DIRECTOR
Sell2026-06-16
VanHimbergen Robert Mofficer: EVP and CFO
Sell2026-06-16
Simmons Jeffrey Ndirector, officer: PRESIDENT, CEO AND DIRECTOR
Sell2026-06-02
Modi Rajeev A.officer: SEE REMARKS
Sell2026-06-02

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

US

Exchange

Beta

1.70

Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.